openPR Logo
Press release

Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project

05-27-2022 10:54 AM CET | Health & Medicine

Press release from: Profacgen

Profacgen, an experienced provider in biological research and drug discovery, provides various ubiquitin services to help customers accelerate research progress and obtain better results.

Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of proteins. Therefore, the study of protein ubiquitination plays an important role in cell biology and drug discovery.

With the comprehensive advanced platform, Profacgen offers its customers the following services:

In Vitro ubiquitin conjugation reactions
Profacgen provides services to perform ubiquitin reactions in vitro and analyze the results.

Assay to measure protein ubiquitination in living cells
Profacgen provides ubiquitin assays that can measure all types of ubiquitination on a target protein in living cells. With the help of bioluminescence resonance energy transfer (BRET) methods, customers are able to study the dynamic ubiquitination of target protein and understand which cellular functions are regulated by ubiquitylation.

Ubiquitin identification and quantification by proteomics analysis
Profacgen offers ubiquitin identification and quantification services for protein in cells or tissues. The work starts from enzymes digestion, peptides enrichment, mass spectrometry analysis and bioinformatics analysis.

Advantages of ubiquitination services offered by Profacgen
Rich and comprehensive services
Professional evaluation and experimental design
Stable platform and accurate data
Timely feedback on project progress

Moreover, to assist scientist better with their drug discovery research, Profacgen has established a comprehensive PROTAC technology platform and services including E3 Ligase and Target Proteins Development, Ligand Discovery and Design, PROTAC In Vitro and In Vivo Evaluations, and Targeted Protein Degradation.

"In addition, we have built a mature computer-aided drug design technology platform, which can greatly accelerate your research process. We offer customized and one-stop PROTAC development services and strive to solve all challenging obstacles during your PROTAC research." Said Crystal, the chief marketing staff at Profacgen.

More detailed information about the custom protein ubiquitination service at Profacgen can be viewed here: https://www.profacgen.com/custom-protein-ubiquitination-services.htm.

Profacgen, Shirley, NY 11967, USA


Email: contact@profacgen.com
Tel: 1-516-855-7709
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA


Profacgen is a state-of-the-art protein service provider located in Long Island, NY, USA. We provide custom protein services in the biological sciences, enabling access to the latest tools, techniques, and expertise with competitive pricing and rapid turnaround time. We serve a broad spectrum of industrial and academic clients with a commitment to delivering high-quality data and customer services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project here

News-ID: 2638269 • Views:

More Releases from Profacgen

Profacgen Enhanced Its Structure-based Virtual Screening (SBVS) Service Recently
Profacgen, a biotechnology company that provides custom protein services in the biological sciences, recently enhanced its structure-based virtual screening service for scientists in the field of drug discovery and lead optimization. In structure-based virtual screening (SBVS), potential compounds are computationally docked into the 3D structure of the biological target using biophysical techniques including X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy, homology modeling, or molecular dynamics simulation. Then, the projected binding affinity

More Releases for PROTAC

Proteolysis Targeting Chimera Protac Market Gains Traction Amid Technological Ad …
New Jersey, US State: "The global Proteolysis Targeting Chimera Protac market in the Healthcare and Pharmaceuticals category is projected to reach USD 5.3 billion by 2031, growing at a CAGR of 23.5% from 2025 to 2031. With rising industrial adoption and continuous innovation in Healthcare and Pharmaceuticals applications, the market is estimated to hit USD 1.2 billion in 2024, highlighting strong growth potential throughout the forecast period." Proteolysis Targeting Chimera (PROTAC)
PROTAC Market to See Booming Growth 2025-2032 | Arvinas, Celgene, Nurix Therapeu …
The Global PROTAC Market is estimated to be valued at USD 0.50 billion in 2025 and is expected to reach USD 2.42 billion by 2032, growing at a compound annual growth rate (CAGR) of 25.3% from 2025 to 2032. According to the latest research from CoherentMI, the PROTAC Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough research,
The PROTAC market is anticipated to experience robust expansion over the forecas …
(Albany, USA) DelveInsight's PROTAC Market Insights report offers an in-depth analysis of existing treatment approaches, upcoming PROTAC therapies, the market share of each therapy, and projected as well as current market size for PROTACs from 2020 to 2034. The data is segmented across the 7 major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The PROTAC market is anticipated to expand considerably
PROTAC Market Set Transforming Therapeutics for Explosive Growth in Targeted Dru …
A new report published by CoherentMI, titled "PROTAC Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the PROTAC market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The Global PROTAC Market is estimated to be valued at USD 0.40 billion in 2024 and is expected to reach USD 2.59 billion by
PROTAC Market Industry Trends, Growth Projections, and Market Share Report 2024 …
A new Report by CoherentMI Market Reports, titled "PROTAC Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the PROTAC market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The Global PROTAC Market is estimated to be valued at USD 0.40 billion in 2024 and is expected to reach USD 2.59 billion
PROTAC Cancer Therapy PROTAC Drugs Clinical Trials Insight
Global Proteolysis Targeting Chimeras PROTAC Therapy Clinical Trials Insight & Market Opportunity Report Highlights: • First PROTAC Drug Approval Expected By 2027 • Insight On More Than 50 PROTAC Drugs In Clinical Trials • Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase • Orphan & Fast Track Designation Insight • PROTAC Drugs Clinical Application & Development Outlook By Indication • Current & Future Market Overview • Global PROTAC Drug Market Dynamics Download Report: https://www.kuickresearch.com/ccformF.php?t=1728551968 PROTACs, or proteolysis-targeting chimeras, have emerged as a